141 related articles for article (PubMed ID: 16822947)
1. Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C.
Bradshaw EL; Li XA; Guerin T; Everson WV; Wilson ME; Bruce-Keller AJ; Greenberg RN; Guo L; Ross SA; Smart EJ
Am J Physiol Cell Physiol; 2006 Dec; 291(6):C1271-8. PubMed ID: 16822947
[TBL] [Abstract][Full Text] [Related]
2. Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.
Wilson ME; Sengoku T; Allred KF
J Cell Biochem; 2008 Apr; 103(5):1598-606. PubMed ID: 17879945
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors.
Allred KF; Smart EJ; Wilson ME
J Biol Chem; 2006 Jan; 281(3):1419-25. PubMed ID: 16299001
[TBL] [Abstract][Full Text] [Related]
4. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.
Dressman J; Kincer J; Matveev SV; Guo L; Greenberg RN; Guerin T; Meade D; Li XA; Zhu W; Uittenbogaard A; Wilson ME; Smart EJ
J Clin Invest; 2003 Feb; 111(3):389-97. PubMed ID: 12569165
[TBL] [Abstract][Full Text] [Related]
5. The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice.
Mencarelli A; Cipriani S; Renga B; Francisci D; Palladino G; Distrutti E; Baldelli F; Fiorucci S
PLoS One; 2010 Oct; 5(10):e13238. PubMed ID: 20949026
[TBL] [Abstract][Full Text] [Related]
6. HIV protease inhibitors-induced atherosclerosis: prevention by alpha-tocopherol.
Munteanu A; Ricciarelli R; Zingg JM
IUBMB Life; 2004 Oct; 56(10):629-31. PubMed ID: 15814462
[TBL] [Abstract][Full Text] [Related]
7. Vitamin E concentrations in adults with HIV/AIDS on highly active antiretroviral therapy.
Itinoseki Kaio DJ; Rondó PH; Luzia LA; Souza JM; Firmino AV; Santos SS
Nutrients; 2014 Sep; 6(9):3641-52. PubMed ID: 25225815
[TBL] [Abstract][Full Text] [Related]
8. Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.
Guo W; Wong S; Pudney J; Jasuja R; Hua N; Jiang L; Miller A; Hruz PW; Hamilton JA; Bhasin S
Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2028-32. PubMed ID: 19762785
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.
Cipriani S; Francisci D; Mencarelli A; Renga B; Schiaroli E; D'Amore C; Baldelli F; Fiorucci S
Circulation; 2013 May; 127(21):2114-24. PubMed ID: 23633271
[TBL] [Abstract][Full Text] [Related]
10. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
11. CD36 overexpression in ritonavir-treated THP-1 cells is reversed by alpha-tocopherol.
Munteanu A; Zingg JM; Ricciarelli R; Azzi A
Free Radic Biol Med; 2005 Apr; 38(8):1047-56. PubMed ID: 15780763
[TBL] [Abstract][Full Text] [Related]
12. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
13. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
14. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
Gisolf EH; Jurriaans S; Pelgrom J; van Wanzeele F; van der Ende ME; Brinkman K; Borst MJ; de Wolf F; Japour AJ; Danner SA
AIDS; 2000 Mar; 14(4):405-13. PubMed ID: 10770543
[TBL] [Abstract][Full Text] [Related]
15. [Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].
Espiau M; Soler-Palacín P; Borrull A; Figueras C
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):319. PubMed ID: 21334110
[No Abstract] [Full Text] [Related]
16. Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway.
Geng J; Yang C; Wang B; Zhang X; Hu T; Gu Y; Li J
Biomed Pharmacother; 2018 Jan; 97():941-947. PubMed ID: 29136772
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
Lichterfeld M; Nischalke HD; Bergmann F; Wiesel W; Rieke A; Theisen A; Fätkenheuer G; Oette M; Carls H; Fenske S; Nadler M; Knechten H; Wasmuth JC; Rockstroh JK
HIV Med; 2002 Jan; 3(1):37-43. PubMed ID: 12059949
[TBL] [Abstract][Full Text] [Related]
18. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
19. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.
Hill A; Sawyer W; Gazzard B
HIV Clin Trials; 2009; 10(1):1-12. PubMed ID: 19362991
[TBL] [Abstract][Full Text] [Related]
20. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
